Therefore, neutralization of NF-kB is an attractive strategy for CLL, which not only has the potential to inhibit the proliferation of CLL cells, but also leads to sensitization to both BCR-targeting agents and conventional chemotherapy. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.